ClinicalTrials.gg
Active, not recruitingNCT07706582Updated Oct 30, 2026

Management of Iron Deficiency Anemia in Hemodialysis Patients

A Phase 2 interventional study of Lactoferrin and IV iron sucrose in Iron Deficiency Anemia (IDA) and ESRD (End Stage Renal Disease), sponsored by Beni-Suef University. Active, not recruiting at 1 site in Egypt. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Beni-Suef University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Nov 2025, registered Jul 2026).
Updated Oct 30, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies testing lactoferrin in Anemia, Iron-Deficiency — 1 open to participants now, 3 under way, none of them phase 3. Lactoferrin · Anemia, Iron-Deficiency.

Enrollment
6th of 13
108 · median 100
Started
2025
the only one that year
Phase 2
3 of 13
none open now
Registered
13th of 13
by date
Lead sponsor
1 of 13
Beni-Suef University

Among the 13 studies testing lactoferrin in Anemia, Iron-Deficiency, this one is the 6th largest by enrollment, is the only one that started in 2025, is one of 3 in phase 2, and was the 13th registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

1 of the 13 studies testing lactoferrin in Anemia, Iron-Deficiency is open now. Recruiting first, the newest first:

Where they have run

About lactoferrin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing lactoferrin in Anemia, Iron-Deficiency, or all of them as a file.
02

Study summary

The aim of this interventional study is to assess the effectiveness of oral lactoferrin in improving hemoglobin levels and correcting iron deficiency anemia in patients with end-stage renal disease (ESRD) on dialysis and also evaluate the impact of lactoferrin on bone health by measuring serum calcium and phosphate and other bone health indicators.

The participants will be divided into 3 groups as follow

  • The Lactoferrin group will receive treatment of oral lactoferrin at a dose of 100 mg twice daily alongside erythropoiesis-stimulating agent (ESA) therapy for three months.
  • The IV Iron group will receive IV Iron therapy with ESA for the same duration
  • The Lactoferrin + IV Iron group will receive both oral lactoferrin at a dose of 100 mg twice daily and IV Iron therapy alongside erythropoiesis-stimulating agent (ESA) therapy for three months.
Read the detailed description

The goal of this clinical trial is to evaluate the therapeutic impact of oral Lactoferrin on correcting iron deficiency anemia and improving bone health in patients diagnosed with end-stage renal disease.

AS End-stage renal disease (ESRD) represents a serious medical, social, and economic burden on any society and requires continuous medical attention and comprehensive healthcare services. Without appropriate treatment, it can be life-threatening.

Anemia is a common complication in individuals with chronic kidney disease (CKD) and has been linked to negative cardiovascular outcomes . Managing anemia often involves the use of erythropoiesis-stimulating agents (ESAs); however, targeting normal hemoglobin levels through ESA therapy has been associated with a heightened risk of cardiovascular events and mortality. To achieve effective anemia control, iron supplementation alongside ESAs plays a crucial role. Iron therapy not only helps elevate hemoglobin levels, but also lowers the necessary dosage of ESAs . However, Iron One of the drawbacks of intravenous (IV) iron administration in hemodialysis patients is its potential link to an increased risk of infections, as suggested by some observational studies-though the evidence remains conflicting and inconclusive.

Lactoferrin, also known as the "red protein," is a cationic glycoprotein from the transferrin family with an exceptionally high affinity for iron-approximately 300 times greater than transferrin. Its red color results from this strong iron-binding property. Its production increases during infection and inflammation It contributes to intestinal iron regulation, enhances the body's defense against microbial infections, acts as an anti-inflammatory agent, Thus, and in contrast to iron therapy, lactoferrin offers several advantages over conventional iron supplements, including better gastrointestinal tolerance, fewer side effects associated with high-dose iron intake, and added anti-inflammatory and antimicrobial properties.

Another complication associated with patients with ESRD is Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD), which is a complex, multifactorial condition characterized by disruptions in mineral metabolism, particularly involving calcium, phosphate, vitamin D and parathyroid hormone (PTH). Impaired kidney function leads to phosphate retention, decreased calcitriol synthesis, and calcium imbalance, triggering secondary hyperparathyroidism. Altogether, these hormonal and biochemical changes contribute to both skeletal complications and cardiovascular risks in CKD patients.

Lactoferrin also promotes bone growth by stimulating osteoblast proliferation, preventing cell death, and inhibiting osteoclast formation. These properties suggest its potential as a therapeutic agent for bone healing and osteoporosis Thus, the current study aims to assess the effect of lactoferrin use in patients with ESRD and receiving dialysis assessing its therapeutic potential in enhancing bone mineral density and correcting anemia in patients with chronic kidney disease

03

Conditions studied

  • Iron Deficiency Anemia (IDA)
  • ESRD (End Stage Renal Disease)
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged over 18
  • Diagnosed with chronic kidney disease (CKD) on maintenance hemodialysis (3 sessions/week).
  • Diagnosed with functional iron deficiency anemia

Exclusion criteria

Exclusion Criteria:

  • Active infection
  • Inflammation (any cause other than CKD)
  • Recent bleeding and recent blood transfusion
  • Patients with decompensated medical conditions
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Active comparator
    Lactoferrin Arm

    The Lactoferrin Arm (36 participants) will receive a treatment of oral lactoferrin at a dose of 100 mg twice daily alongside Erythropoiesis-Stimulating Agent (ESA) therapy for three months.

    Dietary Supplement: Lactoferrin

  • Active comparator
    IV Iron Arm

    The IV Iron arm (36 participants) will receive IV Iron therapy ( Iron Sucrose) three times weekly with ESA for three months

    Drug: IV iron sucrose

  • Active comparator
    Lactoferrin + IV Iron Arm

    The Lactoferrin + IV Iron arm (36 participants) will receive both oral Lactoferrin 100 mg twice daily and IV Iron alongside ESA therapy for three months.

    Dietary Supplement: Lactoferrin · Drug: IV iron sucrose

Interventions

  • Dietary supplementLactoferrin

    oral Lactoferrin - dose : 100 mg twice daily ( total dose= 200 mg daily ) - duration: administered for three months

  • DrugIron sucroseStudies of Iron sucroseIron sucrose pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    IV Iron Sucrose will be administered three times weekly for three months

06

What researchers measure

Primary outcomes

  1. Measure the change in hemoglobin concentration (g/dL) from baseline to 3 months, assessing the efficacy of lactoferrin in correcting anemia.

    Hemoglobin concentration (g/dL) will be measured using automated hematology analyzer as a part of routine complete blood count (CBC) by collecting blood samples at baseline ( before the intervention) and after 3 months ( after 12 week of drug administration or at the end of the study )

    Time frame: Hemoglobin concentration (g/dL) will be measured at baseline and after 3 months (after 12 week of drug administration or at the end of the study)

Secondary outcomes

  1. -Measure the change in other complete blood count parameters including Red Blood Cells, Hematocrit and Mean Corpuscular Volume. -Measure the change in Iron Profile and also in Bone health indicators (Serum calcium and phosphate)

    Iron profile parameters will be measured after serum separation by centrifugation then serum iron and Total Iron Binding Capacity will be determined by automated colorimetric assay

    Time frame: All these parameters will be measured at baseline ( before the intervention) and also after three months (after 12 week of drug administration or at the end of the study )

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 16 phase 2 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 13 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Sep 2026 → Dec 2026 and completion Jan 2027 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2026
First posted
Jul 15, 2026
StartActual
Nov 2, 2025
Primary completionEst.
Dec 2026was Sep 2026
CompletionEst.
Mar 2027was Jan 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Dec 2026
Oct 30, 2026
Study completion
Jan 2027→Mar 2027
Oct 30, 2026
Interventions
Changed IV iron dextran→IV iron sucrose
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Primary completion Sep 2026→Dec 2026
    Study completion Jan 2027→Mar 2027
    Interventions Changed IV iron dextran→IV iron sucrose
    + 1 other change: index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07706582
Responsible party
Marina Essam Albert (Master's Candidate, Department of Clinical Pharmacy, Faculty of Pharmacy, Beni-Suef University) — Principal investigator
First posted
Jul 15, 2026
Start date
Nov 2, 2025
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Marina E Albert, Bachelor of Pharmacy
principal investigator · Beni-Suef University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lactoferrin · Iron sucrose

Start the discussion